Juno Therapeutics, Inc.
JUNO
JUNO was delisted on the 5th of March, 2018.
169 hedge funds and large institutions have $1.97B invested in Juno Therapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 71 increasing their positions, 40 reducing their positions, and 33 closing their positions.
78% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 40
13% more call options, than puts
Call options by funds: $36.6M | Put options by funds: $32.4M
3% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 33
1% less funds holding
Funds holding: 170 → 169 (-1)
25% less capital invested
Capital invested by funds: $2.63B → $1.97B (-$652M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$39.8M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$35M |
| 3 |
DFO
Duquesne Family Office
New York
|
+$15.3M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$10.8M |
| 5 |
BAMCO Inc
New York
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Riverhead Capital Management
Wilmington,
Delaware
|
-$86.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$78.4M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$47.1M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$26.5M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$14.7M |
JUNO Hedge Fund Activity: Q3 2016 in Review
169 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Juno Therapeutics, Inc. (JUNO) for Q3 2016, worth a combined $1.97B — down 25% from $2.63B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new JUNO positions and 33 closed out — a net gain of 1 holder — while 71 added to existing stakes and 40 trimmed.
The largest buyer was State Street, adding an estimated $39.8M. The largest seller was Riverhead Capital Management, exiting entirely with an estimated $86.8M sold.
- 169 institutional investors held Juno Therapeutics, Inc. (JUNO) as of Q3 2016, down from 170 in Q2 2016.
- Funds reported $1.97B of Juno Therapeutics, Inc. stock for Q3 2016, down 25% quarter-over-quarter.
- 34 funds opened new Juno Therapeutics, Inc. positions in Q3 2016 and 33 closed out, a net change of +1 holder.
- The largest Juno Therapeutics, Inc. buyer in Q3 2016 was State Street, an estimated $39.8M added.
- The largest Juno Therapeutics, Inc. seller in Q3 2016 was Riverhead Capital Management, an estimated $86.8M sold.
Based on aggregated 13F filings for Q3 2016.